Lifesci Capital Begins Coverage on Tourmaline Bio (NASDAQ:TRML)

Lifesci Capital initiated coverage on shares of Tourmaline Bio (NASDAQ:TRML) in a research note published on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $58.00 target price on the stock. Lifesci Capital also issued estimates for Tourmaline Bio’s Q4 2024 earnings at ($0.88) EPS and FY2024 earnings at ($2.89) EPS.

Several other brokerages have also weighed in on TRML. Guggenheim reiterated a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of Tourmaline Bio in a research report on Wednesday, December 11th. BMO Capital Markets began coverage on Tourmaline Bio in a report on Friday, December 6th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of Tourmaline Bio in a report on Wednesday, December 11th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $54.67.

Tourmaline Bio Price Performance

Shares of TRML stock opened at $12.94 on Monday. The company has a market capitalization of $331.82 million, a PE ratio of -4.59 and a beta of 2.32. The firm’s 50-day moving average is $17.21 and its two-hundred day moving average is $20.87. Tourmaline Bio has a 12 month low of $11.87 and a 12 month high of $48.31.

Institutional Investors Weigh In On Tourmaline Bio

Several institutional investors and hedge funds have recently modified their holdings of TRML. Woodline Partners LP lifted its stake in Tourmaline Bio by 1.6% during the 4th quarter. Woodline Partners LP now owns 161,721 shares of the company’s stock worth $3,280,000 after acquiring an additional 2,567 shares in the last quarter. Velan Capital Investment Management LP increased its stake in Tourmaline Bio by 28.0% during the fourth quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company’s stock worth $8,595,000 after purchasing an additional 92,605 shares during the period. Wexford Capital LP acquired a new stake in shares of Tourmaline Bio during the fourth quarter worth about $418,000. Stempoint Capital LP grew its holdings in shares of Tourmaline Bio by 127.7% in the fourth quarter. Stempoint Capital LP now owns 126,400 shares of the company’s stock valued at $2,563,000 after purchasing an additional 70,877 shares in the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in shares of Tourmaline Bio in the fourth quarter valued at approximately $605,000. Hedge funds and other institutional investors own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.